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Neurofibrillary tangles (NFTs) are composed of abnormal aggregates of the cytoskeletal protein tau. Together 
with amyloid β (Aβ) plaques and neuronal and synaptic loss, NFTs constitute the primary pathological hall-
marks of Alzheimer disease (AD). Recent evidence also suggests that caspases are activated early in the progres-
sion of AD and may play a role in neuronal loss and NFT pathology. Here we demonstrate that tau is cleaved at 
D421 (ΔTau) by executioner caspases. Following caspase-cleavage, ΔTau facilitates nucleation-dependent fila-
ment formation and readily adopts a conformational change recognized by the early pathological tau marker 
MC1. ΔTau can be phosphorylated by glycogen synthase kinase-3β and subsequently recognized by the NFT 
antibody PHF-1. In transgenic mice and AD brains, ΔTau associates with both early and late markers of NFTs 
and is correlated with cognitive decline. Additionally, ΔTau colocalizes with Aβ1–42 and is induced by Aβ1–42 in 
vitro. Collectively, our data imply that Aβ accumulation triggers caspase activation, leading to caspase-cleavage 
of tau, and that this is an early event that may precede hyperphosphorylation in the evolution of AD tangle 
pathology. These results suggest that therapeutics aimed at inhibiting tau caspase-cleavage may prove benefi-
cial not only in preventing NFT formation, but also in slowing cognitive decline.
Introduction
Tau is a microtubule-associated protein that stabilizes the neuronal 
cytoskeleton and participates in vesicular transport and axonal 
polarity (1–4). In the brain, there are six isoforms of tau, produced by 
alternative mRNA splicing of a single gene located on chromosome 
17. Pathological alterations in tau occur in several neurodegenerative 
disorders, including Alzheimer disease (AD), supranuclear palsy, 
and frontotemporal dementia with parkinsonism (5).
In AD, insoluble neurofibrillary tangles (NFTs) composed of 
hyperphosphorylated forms of tau accumulate initially within 
the entorhinal cortex and CA1 subfield of the hippocampus 
(6–8). Recent studies have begun to clarify the sequence of tau 
alterations that lead to neurodegeneration, including conforma-
tional changes and hyperphosphorylation. Antibodies developed 
against pathological tau have helped to identify these changes. An 
aberrant folded conformational change in tau, recognized with 
antibody MC1, appears to be one of the earliest tau pathological 
events (9–12). The antibody AT8 recognizes tau phosphorylated 
at both serine 202 and threonine 205, which are the first residues 
to be hyperphosphorylated, whereas the antibody PHF-1 recog-
nizes phosphorylation at serines 396 and 404 and reacts with more 
mature hyperphosphorylated forms of tau found primarily within 
late-stage tangles (13–15). Such alterations in tau may reduce its 
binding affinity for microtubules, thereby leading to depolymer-
ization of microtubules and contributing to the neuronal loss 
observed in AD (16–18).
Caspases are cysteine aspartate proteases that are critically involved 
in apoptosis. These enzymes can be broadly divided into initiator and 
executioner caspases, with the former functioning to initiate apopto-
sis by activating executioner caspases and the latter acting on down-
stream effector substrates that result in the progression of apoptosis 
and the appearance of hallmark morphological changes such as cell 
shrinkage, nuclear fragmentation, and membrane blebbing (19). 
Increasing evidence suggests that caspases are activated in the AD 
brain (20–26). Furthermore, components of the neuronal cytoskel-
eton, including tau, are targeted by caspases following apoptotic 
stimuli (23, 27–34). Although the role of tau caspase-cleavage in AD 
pathology remains unresolved, recent evidence now implicates the 
caspase-cleavage of tau in tangle pathology (34). However, in AD, it 
is unclear whether hallmark pathological lesions induce caspases, 
whether caspases contribute to these lesions, or whether both occur.
In this study, we tested the hypothesis that caspase-cleavage of 
tau is an early event in tangle formation in both AD and a trans-
genic model of this disorder. We found that caspase-cleaved tau 
catalyzes filament formation, adopts a conformation found in 
early-stage tangles, and can be hyperphosphorylated. Caspase-
cleavage of tau also colocalizes with amyloid β (Aβ) and develop-
ing tangles in both transgenic mice and the AD brain. In primary 
cortical neurons, Aβ-induced caspase activation leads to tau cleav-
age and generates tangle-like morphology. Thus, our data suggest 
that caspase activation is an early event in NFT formation that can 
be triggered by Aβ, and that caspase activation may contribute to 
an important hallmark lesion of AD.
Results
Tau is cleaved at D421 by executioner caspases. To determine which 
caspases cleave tau, recombinant human tau40 was treated with 
several active caspases. Incubation of tau with caspase-3 or -7, but 
not with caspase-1, -4, -5, -8, or -10, resulted in a 2-kDa electro-
phoretic shift by SDS-PAGE (Figure 1A, arrowhead). Analysis of 
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the cleavage products by electrospray mass spectroscopy revealed 
two tau fragments with molecular weights of 45,900.00 Da (ΔTau) 
and 1,997.99 Da (C-terminus), corresponding to the theoretical 
molecular weights of tau cleaved after amino acid residue D421 
(45,900.80 Da and 1,999.29 Da) (see supplemental data; available 
at http://www.jci.org/cgi/content/full/114/1/121/DC1). Cleavage 
after D421 was also confirmed by primary amino acid sequencing 
of the small fragment (data not shown).
To examine the role of ΔTau in NFT pathology, we generated a 
rabbit polyclonal antibody (α-ΔTau) directed against the caspase-
cleaved carboxy-terminus of tau. The specificity of α-ΔTau was 
confirmed by Western blot analysis and was found to selectively 
recognize the D421-cleaved fragment generated by caspase-3 or -7 
but not full-length tau (Figure 1B). In contrast, a previously gener-
ated antibody that recognizes the C-terminus of tau (T46; ref. 35, 
36) detects full-length tau but not ΔTau (Figure 1C).
Specificity of the α-ΔTau antibody was further assessed, in 
vivo, using traumatic brain injury (TBI), a model that leads to 
neuronal caspase activation (37). Forty-eight hours after injury, 
immunohistochemical analysis confirmed caspase-3 activation 
within both wild-type (Figure 2A, inset) and Tau–/– brains (Figure 
2B, inset). However, ΔTau immunoreactivity was observed within 
wild-type (Figure 2A) but not Tau–/– (Figure 2B) mice following 
TBI. In contrast, caspase-cleaved fodrin, another cytoskeletal 
target of caspases, was observed within both wild-type and tau 
knockout brains (see supplemental data). Therefore, the α-ΔTau 
antibody specifically detects caspase-cleaved tau and does not 
cross-react with other caspase-cleaved substrates in vivo.
ΔTau is prevalent within the AD brain and is inversely correlated with 
cognitive function. To determine whether ΔTau is associated with 
AD neuropathology, AD and control hippocampal sections 
were immunolabeled with the α-ΔTau antibody. We observed 
extensive α-ΔTau labeling within AD hippocampus (Figure 3A). 
In contrast, only occasional ΔTau-positive cells were observed 
in controls (Figure 3B). Preadsorption of the α-ΔTau antibody 
with immunizing peptide led to a loss of all immunoreactivity 
(Figure 3A, inset).
Next, we performed light-level immunohistochemistry to quan-
tify the number of ΔTau-immunoreactive cells within CA1 of AD 
versus control hippocampus (data not shown). Significantly more 
ΔTau-immunoreactive cells were observed in AD than in control 
brains (AD, 28.2 ± 1.65; control, 4.25 ± 0.85; P < 0.05). Further-
more, the number of ΔTau-immunoreactive cells within CA1 of 
AD cases inversely correlated with cognitive function (Mini-Men-
tal State Examination [MMSE] score) (Figure 3C). Thus, ΔTau may 
contribute to cognitive decline in AD.
To assess the relationship between caspase-cleaved tau and full-
length tau pathology, fluorescent double labeling for ΔTau and the 
C-terminal–specific antibody T46 was performed (36). High-power 
confocal imaging revealed an intriguing difference in subcellular 
distribution between these two markers, suggesting that both full-
length tau (T46, green) and cleaved tau (α-ΔTau, red) are present 
within the same NFTs (Figure 3, D and E). T46 immunoreactivity 
was frequently observed surrounding ΔTau immunofluorescence 
in both cell bodies (Figure 3D) and dystrophic neurites (Figure 3E). 
The C-terminal epitope recognized by T46 (35) is liberated by exe-
cutioner caspases (Figure 1C). Therefore, the minimal subcellular 
colocalization of ΔTau and T46 further confirms the cleavage site 
specificity of α-ΔTau.
Tau becomes increasingly insoluble as AD progresses. 
Therefore, we performed sequential fractionation of con-
trol, mild cognitive impairment (MCI), and AD brain lysates 
into high-salt reassembly buffer (RAB) and detergent-soluble 
radioimmunoprecipitation buffer (RIPA) fractions to examine 
the solubility of ΔTau as AD progresses. We found that ΔTau 
recognized multiple caspase-cleaved tau isoforms in both MCI 
and AD cases but not controls within the high-salt soluble RAB 
fraction (Figure 4A). In the detergent-soluble RIPA fraction, 
ΔTau was present within AD cases and also in a more advanced 
MCI-AD transitional case (Figure 4A, asterisk), but not within 
MCI or control cases (Figure 4A). In addition, ΔTau appeared 
to be post-transationally modified (hyperphosphorylation 
or ubiquitination) within the RIPA fraction, as evidenced by 
smeared signal (Figure 4A). Therefore, ΔTau appears to become 
increasingly insoluble as AD advances.
Figure 1
Executioner caspases cleave tau at D421. (A) Recombinant human 
tau40 (Calbiochem) treated with various caspases was separated by 
SDS-PAGE and stained with Coomassie blue. Treatment with cas-
pase-3 (C3) and caspase-7 (C7) resulted in a 2-kDa shift (arrowhead) 
relative to full-length tau (FL), while treatment with caspase-1 (C1), -4 
(C4), -5 (C5), -8 (C8), or -10 (C10) did not (arrow). (B) Western blot 
analysis confirmed the specificity of polyclonal antibody (α-ΔTau) to 
D421 caspase-cleaved tau. α-ΔTau recognized caspase-3– and cas-
pase-7–cleaved tau, but not uncleaved tau. (C) Executioner caspases 
remove the C-terminal epitope of tau that is recognized by antibody 
T46. Full-length and caspase-cleaved tau was probed with mAb T46.
Figure 2
The α-ΔTau antibody specifically recognizes caspase-cleaved tau in 
vivo. Wild-type (A) and Tau–/– (B) mice were subjected to TBI to induce 
caspase activation. Immunofluorescent labeling with an antibody to 
active caspase-3 confirmed caspase activation within both wild-type 
(A, inset) and tau knockout (B, inset) brains. ΔTau immunoreactivity 
was also detected within wild-type brains (A). In contrast, ΔTau 
immunoreactivity was not observed within tau knockout mice following 
TBI (B), which further confirms the specificity of the α-ΔTau antibody 
in vivo. Scale bar: 80 μm (A and B), 20 μm (insets).
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To further elucidate the subcellular distribution of ΔTau in the 
AD brain, immunogold electron microscopy was performed using 
the α-ΔTau antibody. A diffuse distribution of α-ΔTau conjugated 
gold particles was observed in association with tangle-like structures 
within neuronal somata (Figure 4B). In addition, gold particles were 
observed within structurally intact axons (Figure 4C), which indi-
cates that caspase-cleavage of tau may precede neuritic pathology.
ΔTau induces filament formation. To determine whether ΔTau con-
tributes to tangle pathology by promoting filament formation, we 
measured light scattering, which has previously been shown to be 
an effective means of monitoring tau filamentous aggregates (38). 
Tau was incubated in the presence of heparin, which accelerates tau 
aggregation in vitro, so that we could assay filament formation in 
real time (39). We found that caspase-3–cleaved tau (filled squares) 
demonstrated increased light scattering over time (indicative of 
filament formation) and aggregated more rapidly than full-length 
tau (filled diamonds, Figure 5). In addition, ΔTau accelerated fila-
ment formation of full-length tau, as the incubation of full-length 
tau in the presence of ΔTau resulted in a dramatic increase in the 
rate of scattered light (open squares, Figure 5). These results show 
not only that caspase-cleavage of tau leads to increased filament 
formation, but that ΔTau may also act to seed filament formation 
of full-length tau. These data further support a nucleation-depen-
dent mechanism of tau filament assembly (40).
Caspase-cleavage induces a conformational change in tau, which can be 
hyperphosphorylated by glycogen synthase kinase-3β. The increased pro-
pensity of ΔTau to induce filament formation may ensue from a 
conformational change that follows liberation of the C-terminus. 
One of the earliest pathological alterations in tau during AD is a 
conformational change that is recognized by the antibody MC1 
(12). Because the formation of the MC1 epitope occurs prior to 
paired helical filament (PHF) assembly (12), we hypoth-
esized that ΔTau may likewise adopt this conformation. 
Immunoprecipitation with MC1 preferentially recog-
nized ΔTau over full-length tau in three separate experi-
ments (Figure 6A). Therefore, our results show that 
caspase-cleavage of tau induces an early conformational 
change recognized by MC1.
Besides a conformational change, phosphorylation 
of specific residues is another important stage in the 
pathology of tau. Accordingly, we tested whether cas-
pase-cleaved tau can be hyperphosphorylated in vitro. 
Recombinant full-length tau and caspase-cleaved tau 
were incubated at 37°C in the presence of ATP and gly-
cogen synthase kinase-3β (GSK-3β), a kinase implicated 
in the hyperphosphorylation of tau (41). Western blot 
analysis with the tau phospho-epitope antibody PHF-1 
revealed that both ΔTau and full-length tau were 
hyperphosphorylated in vitro by GSK-3β (Figure 6B). 
Although we assayed kinase activity over a 4-hour peri-
od, phosphorylation of ΔTau occurred rapidly within 
1 hour. Therefore, caspase-cleavage does not preclude 
subsequent hyperphosphorylation of tau, which further 
supports the notion that ΔTau may occur early in the 
development of NFT pathology.
ΔTau is observed throughout the evolution of NFT pathol-
ogy in the AD brain. Because ΔTau adopts a conforma-
tion that is recognized by the MC1 antibody and can 
be phosphorylated to form the PHF-1 epitope, we per-
formed triple-labeling experiments with α-ΔTau (red), 
MC1 (green), and fluorescently labeled PHF-1 (blue) to determine 
whether ΔTau colocalized with early (MC1) or late (PHF-1) tau 
pathological alterations in AD (Figure 7). In the AD hippocampus 
and entorhinal cortex, we found both neurons (Figure 7, A–D) and 
dystrophic neurites (Figure 7, E and F) that labeled with ΔTau, 
MC1, and PHF-1. We observed all three labels in pretangle (Figure 
7A), diffuse tangle–bearing (Figure 7B), and mature tangle–bear-
ing neurons (Figure 7, C and D). Interestingly, we did not observe 
Figure 3
ΔTau is found predominantly within AD brain and is inversely correlated with 
cognitive function. Large numbers of ΔTau-immunoreactive neurons (red) were 
observed in the hippocampus and entorhinal cortex of AD brains (A). In contrast, 
only occasional ΔTau-immunoreactive cells were observed in age-matched con-
trol cases (B). Preadsorption of the α-ΔTau antibody with immunizing peptide 
resulted in no immunofluorescence (A, inset). Regression analysis of the num-
ber of hippocampal CA1 cells labeled with α-ΔTau versus AD Mini-Mental State 
Examination (MMSE) scores revealed a significant inverse correlation between 
ΔTau and cognitive function (P = 0.05, r2 = –0.72; (C). High-power confocal 
microscopy demonstrated distinct subcellular localization of ΔTau (red) and the 
C-terminal–specific antibody T46 (green) within cell bodies (D) and dystrophic 
neurites (E). Scale bar: 65 μm (A and B), 8 μm (D), 5 μm (E).
Figure 4
ΔTau becomes increasingly insoluble with disease progression and is 
associated with tangle-like pathology at the ultrastructural level. Control 
(C), MCI, and AD temporal cortex samples were subjected to sequential 
fractionation into high-salt RAB and detergent-soluble RIPA fractions as 
previously described (50, 78) (A). ΔTau was detected in the soluble 
RAB fraction of MCI and AD but not control cases, suggesting that ΔTau 
production coincides with the early stages of cognitive decline in AD. 
In detergent-soluble RIPA fractions, ΔTau was only detected in higher-
pathology MCI and AD cases, which suggests that ΔTau becomes more 
insoluble as AD progresses. *This patient was considered transitional 
between MCI and AD (see Methods). Immunogold electron microscopy 
demonstrated ΔTau at the ultrastructural level in association with early 
tangle-like pathology within a neuronal cell body (B) and a myelinated 
axon (C). Scale bar: 0.4 μm (B), 0.3 μm (C).
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any cells that expressed MC1 and PHF-1 without ΔTau, which 
strengthens our assertion that ΔTau is important in tangle forma-
tion. Finally, triple labeling of plaque-associated dystrophic neu-
rites revealed numerous permutations of the three tangle markers, 
suggesting that dystrophic neurites also show varying degrees of 
AD pathological progression (Figure 7F).
Active caspase-3 colocalizes with ΔTau within pretangle neurons and 
dystrophic neurites of the AD brain. To further examine whether 
caspase activation and caspase-cleavage of tau occur early in the 
formation of tangles, we performed fluorescent double label-
ing for active caspase-3 and ΔTau. We observed colocalization of 
active caspase-3 with ΔTau, specifically within pretangle neurons 
of CA1 (Figure 8A) and dystrophic neurites (Figure 8B). In con-
trast, within mature extracellular tangles, active caspase-3 was not 
observed, possibly because of loss of membrane integrity and cell 
death (Figure 8C). Taken together, these data suggest that caspase 
activation and caspase-cleavage of tau occur early in tangle devel-
opment. However, caspase activation appears to be lost with cell 
death, while ΔTau persists within extracellular NFTs, perhaps as 
insoluble accumulations.
Evidence that ΔTau is induced by Aβ. Aβ activates caspases in 
vitro (42–44). Therefore, we sought to examine whether ΔTau 
colocalized with Aβ in the AD brain. We found that ΔTau (red) 
colocalized with granular intraneuronal Aβ deposits (green) 
within CA1 (Figure 8, D and E). Similar results were observed 
with two different Aβ-specific antibodies (Aβ1–42 and 4G8). ΔTau-
immunoreactive dystrophic neurites were also frequently observed 
in association with Aβ-immunoreactive plaques (Figure 8F). Com-
bined, these data suggest that both intracellular and extracellular 
Aβ may induce caspase-cleavage of tau.
Because we found that Aβ colocalized with ΔTau in the AD brain, 
we determined whether Aβ might induce caspase-cleavage of tau in 
cultured rat primary cortical neurons. Using immunofluorescent 
triple labeling for ΔTau (red), the neuronal marker MAP-2 (green), 
and DAPI (blue), we found a significant increase in ΔTau-positive 
neurons following fibrillar Αβ1–42 treatment (Figure 9). Quantifica-
tion of cell number (see Methods) revealed a significant increase 
in ΔTau-positive cells following Αβ1–42 treatment (F (7,31) = 43.28, 
P < 0.0001). After 6 hours of treatment, a twofold increase in ΔTau-
immunoreactive cells was observed (control, 1.0 ± 0.33 cells; treat-
ed, 2.13 ± 0.35 cells; P = 0.012). However, by 24 hours, the number 
of ΔTau-immunoreactive cells was increased almost ninefold over 
that of untreated cells (control, 0.75 ± 0.37 cells; treated, 6.63 ± 0.38 
cells; P < 0.0001) (Figure 9D). The number of ΔTau-immunoreactive 
cells was not significantly affected after only 1 hour (P = 0.560) or 4 
hours (P = 0.086) of Αβ1–42 treatment. The majority of ΔTau-bear-
ing neurons (91.5%) in control and Αβ1–42-treated cultures con-
tained apoptotic nuclei, as assessed by DAPI (Figure 9, A–C, blue). 
Furthermore, we discovered that ΔTau labeled striking tangle-like 
structures in dying neurons (Figure 9, B and C). Therefore, Aβ1–42 
triggers the production of ΔTau in vitro.
ΔTau is detected early in the progression of tangle pathology in a triple-
transgenic model of AD. To better assess the role of caspase-cleaved 
ΔTau in the pathogenesis of AD, we determined whether ΔTau was 
present in the brains of transgenic mice. We used a recently charac-
terized triple-transgenic mouse (3xTg-AD) that recapitulates many 
salient features of AD: progressively developing intraneuronal 
Aβ, deficits in long-term potentiation, amyloid plaques, and, 
subsequently, NFTs (45). We examined brains from 6- (with only 
Aβ deposits but no NFT pathology), 12- (in the initial stages of 
NFT pathology), and 18-month-old mice (in which both plaque 
and NFT were well established). At 6 months of age, we detected 
intracellular Aβ, but not ΔTau immunoreactivity (data not shown). 
By 12 months of age, we found that ΔTau (red) colocalized with 
intraneuronal Aβ immunoreactivity within CA1 neurons of the 
hippocampus (Figure 10A). In older mice (18 months), Aβ and 
ΔTau colocalized within both CA1 neurons (Figure 10B) and the 
Figure 5
Caspase-cleavage of tau drives filament formation of full-length tau in 
vitro. Laser light scattering was used to assess tau filament formation 
in vitro. Equimolar (4 μM) amounts of ΔTau (filled squares), full-length 
tau (filled diamonds), or a 3:1 ratio of full-length tau to ΔTau (open 
squares) were monitored over 400 minutes. ΔTau (filled squares) scat-
tered light (arbitrary units [AU]) more rapidly and to a greater degree 
than full-length tau (filled diamonds), indicating increased filament for-
mation. Most interestingly, a 3:1 ratio of full-length tau to ΔTau (open 
squares) dramatically accelerated light scattering, suggesting that 
ΔTau may nucleate the assembly of full-length tau filaments.
Figure 6
Caspase-cleavage of tau induces a conformational epitope that is rec-
ognized by the antibody MC1 and can be phosphorylated by GSK3-β. 
(A) MC1, a mAb that recognizes an early tau conformational change, 
was coupled to protein G and used to immunoprecipitate either full-
length (lane 1) or caspase-3–cleaved recombinant tau (lane 2). 
Western blot analysis of immunoprecipitated proteins probed with an 
anti-tau polyclonal antibody revealed an increased affinity of the MC1 
antibody for ΔTau over full-length tau. (B) In vitro phosphorylation of 
ΔTau: Either full-length or caspase-3–cleaved tau was phosphorylated 
with the kinase GSK-3β and then analyzed by Western blot with the 
phosphorylation-dependent antibody PHF-1. Immunoreactivity for 
PHF-1 demonstrates that, like full-length tau (FL), caspase-cleaved 
tau (ΔTau) can be hyperphosphorylated and suggests that caspase-
cleavage of tau does not preclude subsequent hyperphosphorylation. 
Numbers over each lane indicate the number of hours that tau species 
were incubated with GSK-3β. MC1 and PHF-1 experiments were rep-
licated three times, and representative immunoblots are shown.
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neocortex (Figure 10C). This finding closely mimics the progres-
sion of NFT pathology that has previously been reported in 3xTg-
AD mice (45). Next, we investigated whether ΔTau colocalized with 
MC1 in this transgenic model. Colocalization of ΔTau (red) and 
MC1 (green) was first observed within CA1 pyramidal neurons 
at 12 months of age (Figure 10D) and persisted in 18-month-old 
mice (Figure 10, E and F). Interestingly, the subcellular distribu-
tion of ΔTau evolved with increasing age. At 12 months, the great 
majority of ΔTau-immunoreactive cells displayed punctate cleav-
age product within the soma and proximal dendrites of neurons 
(Figure 10, A and D). However, by 18 months of age, many 
ΔTau-bearing neurons exhibited aggregated filamentous 
structures that appeared strikingly similar to AD tangle 
pathology (Figure 10, C and F).
Discussion
Here we demonstrate that caspase-cleavage of tau near the 
carboxy-terminus leads to a conformational change that is pref-
erentially recognized by the early tangle marker MC1. ΔTau also 
accelerates the aggregation of full-length tau filaments and can be 
hyperphosphorylated in vitro. Since ΔTau colocalizes with MC1 
within neurons of subjects with AD and 3xTg-AD mice, we pos-
tulate that caspase-cleavage of tau occurs early in NFT formation. 
This hypothesis is further supported by the presence of ΔTau in 
brain extracts from patients with MCI and the detection of ΔTau 
within pretangle-like structures by electron microscopy. However, 
the fact that ΔTau colocalizes with PHF-1 in the AD brain suggests 
that although ΔTau may occur early in NFT formation, it persists 
throughout the evolution of NFTs.
The kinetics data support a role for ΔTau in seeding tau 
pathology via a nucleation-dependent mechanism. Tau dimer-
ization and subsequent nucleation events are proposed to 
be the rate-limiting step in filament formation (40). Because 
caspase-cleaved tau enhanced the rate of full-length tau fila-
ment formation, we speculate that caspase-cleavage of tau 
may either increase the propensity for tau to dimerize and/or 
affect nucleation-dependent filament assembly. Because MC1-
immunoreactive tau aggregates more readily than recombinant 
tau (12), the adopted MC1 conformation may explain why 
ΔTau enhances filament formation. The MC1 conformation 
may involve the intramolecular interaction between the N- and 
C-termini of tau (folded conformation). Caspase-cleavage of tau 
may initiate the MC1 conformation by removing a portion of 
the C-terminus that inhibits tau aggregation in vitro (46), and 
allowing tau to adopt this conformation.
Figure 7
ΔTau is present throughout the evolution of NFT pathology. Triple 
immunofluorescence was used to examine the association of ΔTau 
(red) with the conformation-sensitive tau antibody MC1 (green) and 
the tau phosphoepitope antibody PHF-1 (blue) in hippocampal NFT 
pathology. ΔTau (red) was coincident with MC1 and PHF-1 throughout 
the evolution of NFT pathology within pretangle neurons (A), diffuse 
tangle–bearing neurons (B), mature tangle–bearing neurons (C and 
D), and dystrophic neurites (E and F). Scale bar: 8 μm (A, C, and D), 
12 μm (B), 4 μm (E), 10 μm (F).
Figure 8
Caspase activation and intracellular Aβ colocalize with ΔTau 
in the AD brain. Fluorescent confocal imaging demonstrated 
that ΔTau (red) and active caspase-3 (green) colocalized 
within pretangle neurons (A) and dystrophic neurites (B) 
of the AD hippocampus. In contrast, mature extracellular 
tangles contained ΔTau without evidence of caspase activa-
tion (C). Intracellular Aβ (green), a known initiator of cas-
pases, colocalizes with ΔTau (red) within AD neurons (D and 
E). In addition, ΔTau-immunoreactive dystrophic neurites 
(red) were frequently associated with extracellular amyloid 
plaques (F). Scale bar: 5 μm (A), 1.5 μm (B), 6 μm (C), 3 μm 
(D and E), 25 μm (F).
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Although isolated PHFs contain truncated tau species (e.g., trun-
cation at Glu391) that may play a role in NFT formation (47, 48), the 
mechanism(s) that gives rise to tau truncation is currently unknown. 
The presence of ΔTau throughout the progression of tangle pathol-
ogy suggests that truncated tau species may arise from further 
proteolysis of ΔTau. However, the presence of both full-length tau 
(T46) and ΔTau in NFTs implicates a role for both full-length and 
caspase-cleaved tau in tangle formation. Although ΔTau colocalized 
with several NFT markers in the AD brain, we have not yet dem-
onstrated the presence of ΔTau within PHFs at the ultrastructural 
level. Future experiments aim to address this caveat.
Hyperphosphorylation of tau is the prevailing hypothesis in the 
development of tangle pathology, since hyperphosphorylation 
can promote PHF self-assembly (49). Transgenic animal models 
(mice, Caenorhabditis elegans, Drosophila) strengthen this hypothesis 
(50–54). Although no previous mechanism has been described 
linking caspase-cleavage and the hyperphosphorylation of tau, the 
appearance of hyperphosphorylated tau following the activation 
of apoptosis suggests that the two events may be closely connected 
(55). Our data show that ΔTau can be hyperphosphorylated after 
caspase-cleavage, therefore suggesting that production of ΔTau 
does not preclude subsequent hyperphosphorylation.
Recent evidence suggests that Aβ accumulation precedes 
NFT formation in the AD brain and can potentiate NFTs in 
transgenic mice (45, 51, 52, 56–58). Furthermore, Aβ-induced 
neurodegeneration requires tau expression and may involve the 
intracellular assembly of pathological tau filaments (59, 60). The 
colocalization of ΔTau with both intraneuronal and extracellular 
Aβ deposits suggests that Aβ accumulation may initiate caspase-
cleavage of tau. The granular appearance of intracellular Aβ is also 
observed in Down syndrome patients with AD (61), indicating 
that intraneuronal Aβ may be a common feature of AD subtypes. 
It has been proposed that intraneuronal Aβ accumulation may 
precede extracellular-plaque pathology in both AD and transgenic 
mouse models (45, 57, 61–63), further suggesting that caspase-
cleavage of tau may occur early in AD pathology. However, the 
notion that intracellular Aβ precedes extracellular-plaque deposi-
tion remains controversial.
Functional decline in AD correlates with increasing tangle pathol-
ogy (56, 64–66). The production of ΔTau correlated with the clinical 
progression of AD. In addition to possibly initiating NFT pathol-
ogy, caspase-cleavage of tau may contribute to neuronal dysfunc-
tion. 3xTg-AD mice develop synaptic dysfunction that coincides 
with intracellular Aβ accumulation (45). Because intracellular Aβ 
colocalized with caspase-cleaved tau in the brains of both sub-
jects with AD and 3xTg-AD mice, ΔTau may contribute to further 
synaptic dysfunction and loss, in vivo. In a C. elegans model of tau 
neurodegenerative disease that displays defects in cholinergic trans-
mission, Kraemer et al. detected a truncated tau species (50). It is 
interesting to speculate that this truncation may be due to caspase-
cleavage and may contribute to the observed synaptic dysfunction.
AD is also characterized by the activation of apoptotic path-
ways. Although the hypothesis that apoptosis plays a role in AD 
neurodegeneration remains controversial, recent evidence suggests 
that caspase activation can occur independent of cell death and may 
be neuroprotective (67–69). In addition, caspase activation is impli-
cated in long-term potentiation and neurite extension (70). However, 
caspase-cleaved tau leads to neurite retraction in vitro (71) and thus 
may contribute to synaptic deficits and cellular demise. Although 
the mechanisms that trigger caspases in the AD brain are currently 
unknown, Aβ, which accumulates in the AD brain, is one of many 
known activators of apoptosis (42, 72). Because caspase activation 
is associated with NFT pathology (20–23, 25, 29), our data support 
Figure 9
Treatment of cortical neurons with Aβ leads to increased ΔTau 
immunoreactivity. Fluorescent triple labeling of rat primary cortical 
neurons for ΔTau (red), MAP-2 (green), and DAPI (blue) following Aβ 
treatment (A–C). A significant increase in ΔTau-positive cells (red) was 
observed after 6 hours (*P = 0.012) and 24 hours (**P < 0.0001) of Aβ 
treatment (D). The great majority of ΔTau-positive cells (91.5%) contained 
apoptotic nuclei as revealed by DAPI (A–C). In addition, ΔTau immuno-
labeling also revealed striate tangle-like morphology in association with 
apoptotic nuclei (B and C). Scale bar: 9 μm (A), 5 μm (B), 7.5 μm (C).
Figure 10
ΔTau colocalizes with pathological features of a triple-transgenic model 
of AD. Fluorescent double labeling of 3xTg-AD mice demonstrates that 
intraneuronal Aβ (green) colocalizes with ΔTau (red) within CA1 pyra-
midal neurons of 12-month-old (A) and 18-month-old (B) 3xTg-AD mice 
and within 18-month-old neocortex (C). ΔTau immunoreactivity (red) 
also colocalizes with an early tangle marker, MC1 (green), within CA1 
pyramidal neurons at both 12-month (D) and 18-month time points (E 
and F). Scale bar: 30 μm (A, D, and E), 20 μm (B), 4 μm (C and F).
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the idea that Aβ-induced caspase activation may lead to pathologi-
cal tau (34, 73). Thus, in AD, Aβ and tau pathologies may be closely 
linked through a common pathway, caspase-mediated proteolysis. 
Furthermore, we observed that ΔTau immunoreactivity defined 
striking tangle-like structures in degenerating neurons, which 
is suggestive of Aβ contributing to tangle pathology (51, 52, 58, 
74). Interestingly, in tau transgenic Drosophila, inhibitors of apop-
tosis suppressed tau-induced neurodegeneration (53). Although 
tau is also hyperphosphorylated in this model, the inhibition of 
neurodegeneration underlies the importance of caspase activation 
and possibly tau caspase-cleavage in this animal model.
Finally, our results are in agreement with a recent study demon-
strating that Aβ leads to caspase-cleavage of tau (34). The authors’ 
findings and ours support a model in which any stimuli capable 
of activating caspases (e.g., oxidative damage, neurotrophic factor 
deprivation, low energy metabolism, mitochondrial dysfunction) 
can initiate NFT pathology. Our preliminary data indicate that 
4-hydroxynonenal, an inducer of oxidative stress and activator of 
caspases, leads to the production of ΔTau in rat primary neurons 
(data not shown). Thus, we have proposed a model describing 
the role of caspase-cleavage of tau in the development of tangle 
pathology (Figure 11). Following any stimulus that results in cas-
pase activation (e.g., Aβ1–42), tau is cleaved at D421 (step 1). Upon 
caspase-cleavage, tau adopts an MC1-immunoreactive conforma-
tion (step 2), which leads to increased filament formation that 
may occur on microtubules (where tau binds in vivo) (step 3) (75). 
Although we do not specifically examine whether caspase-cleaved 
tau results in deficits in kinesin-mediated transport, we speculate 
that ΔTau may block kinesin-mediated anterograde transport akin 
to the overexpression of tau (2, 3). As a protective mechanism in 
order to compensate (relieve the blockage), phosphorylation of tau 
occurs to dissociate it from microtubules (step 4) (16–18). Finally, 
dissociation of phosphorylated tau species leads to destabilization 
of the microtubule network and PHF formation (step 5). Although 
destabilization of microtubules may initially be neuroprotective 
(59), it will eventually lead to the demise of the cell. Our mecha-
nism does not exclude other reported mechanisms leading to tau 
hyperphosphorylation but suggests that caspase-cleavage of tau 
contributes to tau hyperphosphorylation in AD.
Thus, in neurodegenerative diseases where tau pathology occurs 
in the absence of Aβ (e.g., Pick disease and supranuclear palsy), 
other stimuli known to activate caspases may 
be involved in the initiation of NFT pathology. 
Therefore, caspase-cleavage of tau may play an 
important role not only in AD, but also in other 
tauopathies, and may serve as a key target for the 
development of novel therapeutics.
Methods
In vitro caspase-cleavage of tau. To examine the speci-
ficity of caspase-cleavage of tau, 25 μg of recombi-
nant human tau40 (Calbiochem, San Diego, Cal-
ifornia, USA) was incubated with active human 
recombinant caspase-1, -3, -4, -5, -7, -8, or -10 
(Calbiochem; and AG Scientific Inc., San Diego, 
California, USA). The caspase-specific activity was 
adjusted so that all caspases would cleave 1 nmol 
of substrate per hour at 37°C. Caspase digestion 
was performed (4 hours, 37°C), and cleavage reac-
tions were terminated by addition of 10% formic 
acid (1 μl). Full-length or caspase-treated recombinant tau (30 ng) 
was separated by 10% SDS-PAGE and either stained with Coo-
massie blue or analyzed by Western blot, as described below.
Electrospray mass spectrometry. Samples were analyzed using an 
HPLC-Micromass Q-TOF 2 (Waters, Milford, Massachusetts, 
USA) using a hand-packed C8 silica column. The flow rate 
was split from 100 μl to 400 nl/min over a 60-minute gradient 
(3–70% acetonitrile). Deconvolution of the spectra was performed 
to identify protein masses (MaxEnt 1 software; Micromass, Man-
chester, United Kingdom).
Generation of α-ΔTau polyclonal antibody. The peptide SSTGSID-
MVD corresponding to the carboxy-terminus of tau following 
caspase-cleavage was conjugated to keyhole limpet hemocyanin 
and injected into rabbits. Research Genetics Inc. (Huntsville, Ala-
bama, USA) performed the synthesis of peptides, injections of 
immunogens, and collection of antisera. The peptide CSTGSID-
MVD was covalently linked to a gel column (SulfoLink kit; Pierce 
Biotechnology Inc., Rockford, Illinois, USA) and used to affinity-
purify antisera from individual rabbits.
Transgenic mice. All rodent experiments were performed in accor-
dance with animal protocols approved by the Institutional Animal 
Care and Use Committee at either the University of California, 
Irvine (UCI), or Duke University (TBI experiments). The triple-
transgenic mice (3xTg-AD) have been described previously (45). 
Briefly, these mice harbor a knock-in mutation of presenilin 1 
(PS1M146V), the Swedish double mutation of amyloid precursor 
protein (APPKM670/671NL), and a frontotemporal dementia muta-
tion in tau (tauP301L) on a 129/C57BL/6 background. Homozygous 
mice were sacrificed by CO2 asphyxiation at 6-month, 12-month, 
and 18-month time points, and brains were rapidly removed and 
immersion-fixed in 4% paraformaldehyde for 48 hours. Coronal 
sections were cut on a Vibratome (Technical Products Interna-
tional, St. Louis, Missouri, USA) (50 μm) and stored in PBS, 0.02% 
NaN3 (4°C), until use. Tau–/– mice (129/C57BL/6 background) 
have been previously described (76). Closed-head injury was 
performed in male tau knockout and wild-type mice (age 12–14 
weeks) with a pneumatic impactor as previously described (77). 
Forty-eight hours after injury, mice were deeply anesthetized and 
transcardially perfused (4% paraformaldehyde). Following post-
fixation, brains were cut and stored as detailed above. All mice 
used in this study were maintained and housed in accordance 
Figure 11
Proposed model for the evolution of NFTs. Apoptotic stimuli such as Aβ1–42 exposure 
result in caspase-cleavage of tau after D421 (I). Caspase-cleaved tau rapidly adopts 
the MC1 conformational epitope (II), which leads to increased filament formation and 
tau aggregation (III). To compensate for tau aggregation, tau may subsequently be 
hyperphosphorylated and disassociate from the microtubule (IV). As a result, caspase-
cleavage of tau may lead to PHF formation (V).
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with NIH and Association for Assessment and Accreditation of 
Laboratory Animal Care guidelines.
Human subjects. Postmortem human brain tissues were obtained 
from the Institute for Brain Aging and Dementia Tissue Repository 
at UCI. A total of 12 neuropathologically confirmed AD cases, three 
cases with MCI, and 11 nondemented control cases, matched for both 
mean age and postmortem interval, were examined. Case demograph-
ics are presented in Supplemental Table 1. Brain sections fixed in 4% 
paraformaldehyde and containing the midregion of the hippocampus 
and entorhinal cortex were cut as described above. For Western analy-
sis, superior temporal gyri from control, MCI, and AD cases under-
went sequential fractionation, as described below. We also included 
a transitional AD case (*MCI). This patient fell outside the normal 
range of MCI but did not meet the criteria for AD dementia.
Clinical diagnoses. Control cases exhibited no memory impairment 
and were normal on tests of functional ability. MCI was diagnosed 
by neuropsychological and neurological examination (at the Insti-
tute for Brain Aging and Dementia, UCI) as previously described 
(78). MCI individuals were not demented but had memory decline 
and scored at least 1.5 SD below the mean of their age-matched 
peers on objective tests of episodic memory (e.g., Consortium to 
Establish a Registry for Alzheimer Disease [CERAD]; Word list test, 
Logical memory test). In addition, these individuals performed 
within normal limits on all other tests of cognitive functioning 
and had no significant deficits in measures of functional abil-
ity (e.g., Dementia Rating Severity Scale and Functional Activity 
Questionnaire).QuestionnaireAD cases were severely impaired in 
memory tasks and measures of functional ability and daily living.
Immunohistochemistry and confocal microscopy . Light-level 
immunohistochemistry was performed using an avidin-biotin 
immunoperoxidase technique (ABC kit; Vector Laboratories Inc., 
Burlingame, California, USA) and was visualized with diamino-
benzidine as previously described (22). Fluorescent immunolabel-
ing followed either a standard two-way technique (primary anti-
body followed by fluorescent secondary antibody) or a three-way 
protocol (primary antibody, biotinylated secondary antibody, and 
then streptavidin-conjugated fluorophore). Free-floating sections 
were rinsed in PBS (pH 7.4) and then blocked (0.25% Triton X-100, 
5% normal goat serum in PBS) for 1 hour. Sections were incubated 
in primary antibody overnight (4°C), rinsed in PBS, and incubated 
(1 hour) in either fluorescently labeled anti-rabbit or anti-mouse 
secondary antibodies (Alexa 488 or 568, 1:200; Molecular Probes 
Inc., Eugene, Oregon, USA) or biotinylated secondary antibodies 
(1:150; Vector Laboratories Inc.) followed by streptavidin–Alexa 
488 (1:200). When two monoclonal or two polyclonal antibodies 
were used in combination (e.g., MC1 and PHF-1), one antibody 
was detected using a standard fluorescent secondary antibody. 
The second epitope was detected by direct conjugation of a fluoro-
phore to the primary antibody (Zenon kit; Molecular Probes Inc.). 
Antibodies were diluted as follows: ΔTau, 1:1,000; T46, 1:1,000 
(Zymed Laboratories Inc., South San Francisco, California, USA); 
active caspase-3, 1:100 (Promega Corp., Madison, Wisconsin, 
USA); caspase-cleaved fodrin, 1:100 (Cell Signaling Technology 
Inc., Beverly, Massachusetts, USA); MC1 and PHF-1, 1:500 (gifts 
of P. Davies, Yeshiva University, Bronx, New York, USA); Aβ1–42, 
1:100 (Biosource International Inc., Camarillo, California, USA); 
Aβ17–24 (clone 4G8), 1:100 (Chemicon International Inc., Temec-
ula, California, USA); MAP-2, 1:2,000 (Sigma-Aldrich, St. Louis, 
Missouri, USA). DAPI (1:400; Molecular Probes Inc.) was used to 
assess apoptotic nuclei in vitro. Omission of primary antibody or 
use of preimmune IgG eliminated all labeling (data not shown). 
In addition, preadsorption of α-ΔTau antibody with an excess 
of immunizing peptide resulted in no immunoreactivity (Figure 
3A, inset). Confocal images were captured on FluoView (Olympus 
America Inc., Melville, New York, USA) or MRC 1024 (Bio-Rad, 
Hercules, California, USA) confocal systems. In some cases images 
were pseudocolored to maintain consistent use of color for a given 
antigen throughout all figures. To prevent signal bleed-through, 
all fluorophores were excited and scanned separately using appro-
priate laser lines and filter sets.
Quantification of ΔTau and correlation with MMSE score. Using the 
human postmortem tissues described above, the relationship 
between ΔTau-immunoreactive cell number and cognitive func-
tion was examined. Sections from AD and control cases (n = 8) 
were immunolabeled for ΔTau using a standard avidin-biotin 
immunoperoxidase technique. The number of ΔTau-positive cells 
within control and AD sections was counted from ×20 photo-
graphs of two randomly chosen regions of CA1. Cell counts were 
averaged and statistically compared by Student’s t test. The rela-
tionship between ΔTau-positive cell number and MMSE score was 
then determined by Spearman’s correlation test. Only AD cases 
were included in the analysis, since control cases can act as ordi-
nate values and artificially increase correlation strength and sig-
nificance. All statistical analyses were performed using StatView 
5.1 (SAS Institute Inc., Cary, North Carolina, USA).
Analysis of ΔTau solubility. Superior temporal gyri of control, MCI, 
and AD cases were processed to isolate RAB and RIPA fractions 
using previously described protocols (50, 79). Briefly, frozen tis-
sue was homogenized in 2 ml/g of RAB-HS (0.1 M 2-(N-morpho-
lino) [MES], 1 mM EGTA, 0.5 mM MgSO4, 0.75 M NaCl, 0.02 M 
NaF, 1 mM PMSF, and 1% protease inhibitor cocktail [P8340; 
Sigma-Aldrich]) and centrifuged at 40,000 g for 40 minutes, and 
the supernatant (RAB fraction) was collected. The RAB-HS pellets 
were rehomogenized in RAB-HS containing 1 M sucrose and cen-
trifuged at 40,000 g for 20 minutes. The pellets were subsequently 
resuspended in RIPA (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% 
Na deoxycholate, 1% NP-40, 5 mM EDTA, 1 mM PMSF, 1 mM 
NaF, 1 mM Na3VO4, and 1 μg/ml aprotinin, leupeptin, and pep-
statin) at 1 ml/g and centrifuged at 40,000 g for 20 minutes, and 
the resulting RIPA-soluble supernatant was collected. BCA protein 
assay (Pierce Biotechnology Inc.) was performed to determine pro-
tein concentration, and equal protein amounts of RAB and RIPA 
fractions were then analyzed by Western blot.
Western blot analysis. Recombinant tau proteins and brain lysates 
were processed for Western blot. Briefly, proteins were separated by 
10% SDS-PAGE and transferred to nitrocellulose (0.2 μm; Schleich-
er & Schuell BioScience Inc., Keene, New Hampshire, USA). Mem-
branes were incubated in either α-ΔTau (1:1,000) or T46 (1:1,000). 
Primary antibody was visualized using either goat anti-rabbit or 
anti-mouse HRP-linked secondary antibody (1:1,000; Calbio-
chem), followed by ECL detection (Pierce Biotechnology Inc.).
Electron microscopy. Tissue from AD cases was embedded in Lowic-
ryl (Ted Pella Inc., Redding, California, USA), and ultrathin sections 
were immunolabeled using a post-embedding procedure (80) with 
ΔTau primary antibody (1:300), followed goat anti-rabbit IgG that 
was previously conjugated to 10 nm gold particles (1:20; Ted Pella 
Inc.). Following incubation in secondary antibody, the sections were 
counterstained with uranyl acetate and lead citrate and examined 
with a Philips CM 10 electron microscope (Phillips Electronic Instru-
ments, Mahwah, New Jersey, USA).
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Laser light scattering. Laser light scattering (LLS) was performed 
as previously described with slight modifications (38, 40, 47). 
Briefly, tau (4 μM) was resuspended in 10 mM HEPES (pH 7.4), 16 
μM heparin, 5 mM DTT, and 0.1% NaN3, and the amount of scat-
tered light was assessed. The degree of light scattering was moni-
tored (room temperature, 400 minutes) in a Fluorometer Micro 
Cell (3 mm; Starna Cells Inc.) illuminated by a He-Ne laser (632 
nm). Light scattering was recorded with a charged coupled device 
(CCD) digital video camera (PL-A641; PixeLINK, Ottawa, Ontario, 
Canada) attached to a microscope objective (×4) positioned at 90° 
to the direction of the incident laser beam. Resultant scatter signal 
intensities were subtracted from signal adjacent to the nonillumi-
nated area (background subtraction). LLS recording software was 
written by W.E. van der Veer (UCI Chemistry Core Facility) using 
LabView (National Instruments, Austin, Texas, USA).
MC1 immunoprecipitation. Full-length and caspase-3–cleaved 
recombinant tau was immunoprecipitated overnight (4°C) with 
mAb MC1 coupled to protein G (Pierce Biotechnology Inc.). 
Immunoprecipitated proteins were eluted with sample buffer 
and analyzed by Western blot using a rabbit polyclonal anti-tau 
primary antibody (1:1,000; gift of L.I. Binder). Membranes were 
then incubated with HRP-linked anti-rabbit secondary antibody 
(1:1,000; Calbiochem) and detected with chromogen 4CN (Perki-
nElmer Inc., Massachusetts, USA).
In vitro phosphorylation assay. Full-length or caspase-3–cleaved 
recombinant tau was purified using TALON metal affinity resin (BD 
Biosciences — Clontech, Palo Alto, California, USA) to remove active 
caspase-3 prior to in vitro phosphorylation assays. All reactions were 
carried out at 37°C in 40 mM HEPES (pH 7.2), 3 mM MgCl2, 5 mM 
EGTA, and 2 mM ATP. Fresh ATP was added immediately before 
GSK-3β (Calbiochem). Aliquots were removed at various time points, 
and reactions were stopped by the addition of sample buffer, boiled 
at 100°C (10 minutes), and analyzed by Western blot.
Aβ treatment of rat cortical neurons. Primary cortical neurons (E18) 
were plated on poly-L-lysine–coated coverslips (1.5 × 105 cells per 
coverslip). After 7 days in culture, cells were treated with 25 μM 
fibrillar Aβ1–42 (Biosource International Inc.) for 1, 4, 6, or 24 
hours. Fibrillar Aβ1–42 was prepared by freeze-thawing (three times) 
followed by incubation at room temperature overnight. Follow-
ing treatment, cells were fixed in 4% paraformaldehyde and pro-
cessed for immunocytochemistry as described above. The number 
of ΔTau, MAP-2, and ΔTau cells with DNA fragmentation (DAPI) 
within a defined counting frame (500 μm2) were quantified with 
a ×20 objective under epifluorescence illumination by a blinded 
observer. Four randomly chosen regions were counted from two 
coverslips per treatment. Data were analyzed using ANOVA for a 
split-plot design followed by Fisher’s protected least significant 
difference post hoc analysis. All statistical analyses were performed 
using StatView 5.1 (SAS Institute Inc.).
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